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Case Report:
Devic's disease or Neuromyelitis Optica is a serious, a 
rare idiopathic  inflammatory neurological disorder 
which affects the optic nerve and the spinal cord. It is a 
severe demyelinating disorder of the nervous system 
characterized by recurrent attacks on the optic nerve 
and spinal cord with or without recovery and maybe 
fatal (1) In most cases, the etiology of Neuromyelitis 
Optica isn’t specific and it is believed to be an 
immunological disorder (2). A few studies have detected 
high titers of anti-Epstein-Barr virus (3) antibody in 
patients suffering from the disease and a possible 
association with tuberculosis (4) Neuromyelitis Optica 
has worldwide distribution and poor prognosis. It 
causes a sudden or gradual loss of vision in one or both 
eyes, varying degrees of weakness or paralysis of legs 
or arms, loss of sensation and bladder and bowel 
dysfunction. Originally the disorder was considered to 
be a variant of multiple sclerosis (MS), but clinical, 
pathological, radiological and immunological data of 
this disease have permitted clearer differences 
between both the diseases and lead to a novel 
definition of this clinical entity (5) The course of NMO is 
more severe and treatment strategies to prevent further 
attacks are different, therefore, it is important to 
differentiate between NMO and MS. Immunotherapy to 
prevent relapses of MS does not effectively prevent 
recurrent NMO attacks (6). The advent of NMO antibody, 
the specific biomarker AQP4-IgG, is an additional 
criterion to support the diagnosis of NMO (sensitivity 
and specificity is 91% and 100%) (7)
CASE PRESENTATION:
We present here a case of a 15-year-old female 
patient, coming from a poor socioeconomic 
background, complaining of weakness in the lower 
limbs and urine retention. The medical history of our 
patient includes a gradual loss of vision at the age of 8 
over the course of 3 years, losing her vision completely 
at the age of 11. No neurological diseases were 
reported in the family. The patient was hospitalized 
before in 2015 due to weakness in the lower limbs and 
facial droop. MRI scan of the brain showed no lesions. 
Fundus examination showed bilateral optic atrophy. 
(Figure. 1.0) Intermittent generalized slow waves were 
seen throughout the EEG record. She was treated with 
methylprednisolone and diagnosed with multiple 
sclerosis at the time and discharged. At this time she 
wasn’t on an disease modifying therapy.  The patient’s 
financial constraints have been a great hurdle in the 
diagnosis and management of her condition. 
with fever, headache, joint and muscle pain, and 
decreased platelets (thrombocytopenia). It is caused by 
Figure 1.0: Fundus examination showed bilateral 
optic atrophy (encircled)
Her symptoms improved gradually, but ever since then 
she has experienced varying degrees of paralysis in the 
upper and lower limb, urinary retention and 
constipation every year and has been hospitalized to 
treat these symptoms Before being admitted here, she 
has had admission 4 times previously in Government 
Hospitals with no definitive diagnosis. The patient has 
been prescribed carbamazepine, azathioprine, and 
prednisolone to treat her spastic paraparesis episodes. 
15 days ago, she presented to the hospital complaining 
of progressive weakness in her legs, spasticity, 
hyperreflexia and urine retention. On ophthalmological 
examination, the absent pupillary light reflex was 
observed. Ocular examination revealed the patient had 
bilateral nystagmus 
(horizontal and coarse). 
Her visual acuity had no 
perception of light (NPL) 
in both eyes and the 
pupils were non-reactive 
to light. Anterior segment 
was normal in both eyes. 
Neurological exam 
showed grade 5 strength 
in upper limbs and grade 
3 strength in the lower 
limbs. The patient was vitally and hemodynamically 
stable but her. T2-weighted MRI of the thoracic spine 
revealed high-intensity signal changes in the spinal 
cord involving both halves extending from D2 to D9. 
Similar changes were noted in the cord at L1 and L2. 
Diffuse edematous signals in entire cervico-dorsal cord 
with mild post-contrast enhancement was observed on 
T2 weighted MRI of the thoracic spine. (Figure. 2 There 
was no cord swelling and focal thinning was seen in the 
lower cervical cord. 
The patient was diagnosed with acute transverse 
myelitis after observing the MRI results and 
Neuromyelitis Optica was suspected. Advanced 
immunological tests performed at Shifa International 
Hospital confirmed the presence of 
aquaporin-4-immunoglobulin G antibodies and the 
patient was diagnosed with Neuromyelitis Optica as she 
fulfilled both the major and minor diagnostic criterion of 
the disease. Improvement in her symptoms was seen 
after she was started on 5mg of prednisolone and went 
through 5 plasmapheresis sessions. 
The patient’s electrolytes were monitored regularly as 
her lab reports showed low levels of potassium and 
magnesium. Neurological examination before 
discharge showed grade 4 strength in her lower limbs 
and she could walk with assistance. No improvement in 
vision was observed.
Figure 2: MRI - Spine showing the radiologic 
finding of the patient T2-weighted MRI of the 
thoracic spine revealed high-intensity signal 
changes in the spinal cord involving both halves 
extending from D2 to D9.  
DISCUSSION
Through this study, we highlight the complexity of 
diagnosing neuromyelitis optica and the treatment 
challenges when socioeconomic factors are a hurdle. 
Because of lack of funding in public hospitals, 
plasmapheresis and the advanced immunological test 
of NMO was delayed. Patients’ family was also 
reluctant to go through these tests and procedures due 
to financial constraints.  The patient presented with 
typical symptoms of NMO but was diagnosed as a case 
of MS before she was presented to us. Differential 
diagnosis between Longitudinal Extensive Transverse 
Myelitis (LETM) that occurs in MS and NMO and SLE is 
important since different therapeutic regimens are 
required and interferon treatment may cause a flare-up 
of the diseases (5,7,8). NMO is quite similar to the 
optico-spinal form of MS hence it can be 
misdiagnosed, however, the course of NMO is more 
acute. Optic neuritis is severe with poor prognosis (9), 
our patient had a very severe case of optic neuritis and 
lost her vision irreversibly.
NMO Ig antibody is a highly specific diagnostic marker 
for NMO. NMO is a rare pathological entity with 
neurological manifestations. Previous literature 
suggests that in patients’ with SLE or Sjogren’s 
syndrome positive NMO IgG is not a secondary effect 
but possibly these patients have two autoimmune 
disorders (10,11). In other studies, the presence of NMO 
IgG has been considered as a predictor for the 
manifestation of NMO spectrum disorder and predicts 
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relapse of the disease. Co-existence of NMO is other 
autoimmune disorders either organ-specific or 
non-specific results in a poorer prognosis (12).
The current diagnostic criteria for NMO requires the 
presence of optic neuritis and acute transverse myelitis 
along with supportive criteria which include aquaporin 4 
seropositivity  normal brain magnetic resonance 
imaging or not meeting the criteria for multiple sclerosis 
and longitudinally extensive cord lesion extending over 
3 or more vertebral segments (7). Our patients 
radiological and serums results fulfilled the diagnostic 
criteria and all 3 supportive criteria were present.
The common initial therapy for acute attacks of NMO is 
intravenous corticosteroids. In some studies, total 
remission was obtained after prednisolone treatment. 
Patients who do not benefit from corticosteroid therapy 
may benefit from plasmapheresis (7).  Our patient went 
through 5 plasmapheresis sessions and was given 5 
mg of prednisolone during her stay. The first line 
therapy suggested for NMO is azathioprine combined 
with prednisolone and rituximab whereas 
cyclophosphamide, mitoxantrone, and mycophenolate 
mofetil are the second line (14). However, it is unclear 
that if NMO with other autoimmune disorders requires 
different treatment regimens.
The prognosis for NMO varies, studies have shown that 
20% of the patient are functionally blind in one eye and 
31% developed monoplegia/paraplegia. The 5-year 
survival rate in patients with paraplegia was 91% (13)
CONCLUSION:
NMO is a rare but severe devastating disease affecting 
vision and nervous system resulting in blindness and
paraplegia in children. Hence an early intervention with 
the appropriate treatment modality in patients
suspected with NMO decides on the favorable outcome 
from an acute episode.
CONSENT: 
Informed consent was taken prior to the writing of this 
case report from the patient.
ABSTRACT:
Devic's disease or Neuromyelitis Optica is a serious, rare idiopathic neurological disorder which affects the optic nerve 
and the spinal cord. A 15-year-old girl was admitted in the neurology was with a previous history of 4 episodes of 
weakness in both the lower limbs and urinary retention. The patient gradually lost her eyesight in both eyes at the age 
of 8. Initially, she was diagnosed as a case of Multiple Sclerosis at the age of 11 when she presented with first episode 
of lower limb weakness. Later, Seropositivity for Aquaporin 4 IgG and clear MRI scan of the brain confirmed the 
diagnosis of Neuromyelitis Optica.
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Fundus examination showed bilateral optic atrophy. 
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seen throughout the EEG record. She was treated with 
methylprednisolone and diagnosed with multiple 
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financial constraints have been a great hurdle in the 
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with fever, headache, joint and muscle pain, and 
decreased platelets (thrombocytopenia). It is caused by 
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Her symptoms improved gradually, but ever since then 
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was no cord swelling and focal thinning was seen in the 
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Hospital confirmed the presence of 
aquaporin-4-immunoglobulin G antibodies and the 
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fulfilled both the major and minor diagnostic criterion of 
the disease. Improvement in her symptoms was seen 
after she was started on 5mg of prednisolone and went 
through 5 plasmapheresis sessions. 
The patient’s electrolytes were monitored regularly as 
her lab reports showed low levels of potassium and 
magnesium. Neurological examination before 
discharge showed grade 4 strength in her lower limbs 
and she could walk with assistance. No improvement in 
vision was observed.
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changes in the spinal cord involving both halves 
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important since different therapeutic regimens are 
required and interferon treatment may cause a flare-up 
of the diseases (5,7,8). NMO is quite similar to the 
optico-spinal form of MS hence it can be 
misdiagnosed, however, the course of NMO is more 
acute. Optic neuritis is severe with poor prognosis (9), 
our patient had a very severe case of optic neuritis and 
lost her vision irreversibly.
NMO Ig antibody is a highly specific diagnostic marker 
for NMO. NMO is a rare pathological entity with 
neurological manifestations. Previous literature 
suggests that in patients’ with SLE or Sjogren’s 
syndrome positive NMO IgG is not a secondary effect 
but possibly these patients have two autoimmune 
disorders (10,11). In other studies, the presence of NMO 
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relapse of the disease. Co-existence of NMO is other 
autoimmune disorders either organ-specific or 
non-specific results in a poorer prognosis (12).
The current diagnostic criteria for NMO requires the 
presence of optic neuritis and acute transverse myelitis 
along with supportive criteria which include aquaporin 4 
seropositivity  normal brain magnetic resonance 
imaging or not meeting the criteria for multiple sclerosis 
and longitudinally extensive cord lesion extending over 
3 or more vertebral segments (7). Our patients 
radiological and serums results fulfilled the diagnostic 
criteria and all 3 supportive criteria were present.
The common initial therapy for acute attacks of NMO is 
intravenous corticosteroids. In some studies, total 
remission was obtained after prednisolone treatment. 
Patients who do not benefit from corticosteroid therapy 
may benefit from plasmapheresis (7).  Our patient went 
through 5 plasmapheresis sessions and was given 5 
mg of prednisolone during her stay. The first line 
therapy suggested for NMO is azathioprine combined 
with prednisolone and rituximab whereas 
cyclophosphamide, mitoxantrone, and mycophenolate 
mofetil are the second line (14). However, it is unclear 
that if NMO with other autoimmune disorders requires 
different treatment regimens.
The prognosis for NMO varies, studies have shown that 
20% of the patient are functionally blind in one eye and 
31% developed monoplegia/paraplegia. The 5-year 
survival rate in patients with paraplegia was 91% (13)
CONCLUSION:
NMO is a rare but severe devastating disease affecting 
vision and nervous system resulting in blindness and
paraplegia in children. Hence an early intervention with 
the appropriate treatment modality in patients
suspected with NMO decides on the favorable outcome 
from an acute episode.
CONSENT: 
Informed consent was taken prior to the writing of this 
case report from the patient.
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